Literature DB >> 22866087

Construction of a fusion expression plasmid containing the G250 gene and human granulocyte-macrophage colony stimulating factor and its significance in renal cell carcinoma.

Jun-Wu Li1, Jun-Yuan Gong, Ke Li, Yan Liu, Qiu-Ping Ye, Xin Liu, Ze-Xuan Su.   

Abstract

This study aimed to construct a eukaryotic expression plasmid containing the G250/MN/CA IX (G250) and human granulocyte-macrophage colony stimulating factor (hGM-CSF) genes, and to detect the expression of these proteins in vitro by recombinant plasmids in eukaryotic cells. pORF-hGM-CSF and pcDNA3.0-G250 were used as the template to amplify G250 and hGM-CSF by routine polymerase chain reaction (PCR). The two PCR products were cloned into the eukaryotic vector pVAX1, in order to construct a recombinant plasmid pVAX1-G250-hGM, and the plasmid was transfected into human embryonic kidney 293 cells. The protein expression was then determined by immunocytochemistry, atomic force microscopy, ELISA and Western blotting. DNA sequencing showed that the cloned G250 and hGM-CSF sequences were consistent with the reported Gene Bank ones. Moreover, a high expression was noted following recombinant plasmid transfection of the G250 and hGM-CSF proteins. Thus, the eukaryotic expression vector pVAX1-G250-hGM containing G250 and hGM-CSF was constructed, allowing for the investigation of the anti-G250 antigen vaccine and immune response mechanisms of biological immunotherapy in renal cell carcinoma.

Entities:  

Year:  2010        PMID: 22866087      PMCID: PMC3410604          DOI: 10.3892/ol.2010.230

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  13 in total

Review 1.  Recent advances in kidney cancer and metastatic disease.

Authors:  Z Kirkali; E Tuzel; M U Mungan
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

2.  Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis.

Authors:  Mario Cruciani; Carlo Mengoli; Giovanni Serpelloni; Romualdo Mazzi; Oliviero Bosco; Marina Malena
Journal:  Vaccine       Date:  2006-08-22       Impact factor: 3.641

3.  Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney.

Authors:  E Oosterwijk; D J Ruiter; P J Hoedemaeker; E K Pauwels; U Jonas; J Zwartendijk; S O Warnaar
Journal:  Int J Cancer       Date:  1986-10-15       Impact factor: 7.396

4.  The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes.

Authors:  J L Vissers; I J De Vries; M W Schreurs; L P Engelen; E Oosterwijk; C G Figdor; G J Adema
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

5.  Renal cell carcinoma guideline.

Authors:  Börje Ljungberg; Damian C Hanbury; Marcus A Kuczyk; Axel S Merseburger; Peter F A Mulders; Jean-Jacques Patard; Ioanel C Sinescu
Journal:  Eur Urol       Date:  2007-03-28       Impact factor: 20.096

6.  The role of carbonic anhydrase IX overexpression in kidney cancer.

Authors:  Thambi Dorai; Ihor S Sawczuk; Jaromir Pastorek; Peter H Wiernik; Janice P Dutcher
Journal:  Eur J Cancer       Date:  2005-12       Impact factor: 9.162

7.  Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.

Authors:  Kenzaburo Tani; Miyuki Azuma; Yukoh Nakazaki; Naoki Oyaizu; Hidenori Hase; Junko Ohata; Keisuke Takahashi; Maki OiwaMonna; Kisaburo Hanazawa; Yoshiaki Wakumoto; Kouji Kawai; Masayuki Noguchi; Yasushi Soda; Reiko Kunisaki; Kiyoshi Watari; Satoshi Takahashi; Utako Machida; Noriharu Satoh; Arinobu Tojo; Taira Maekawa; Masazumi Eriguchi; Shinji Tomikawa; Hideaki Tahara; Yusuke Inoue; Hiroki Yoshikawa; Yoshitsugu Yamada; Aikichi Iwamoto; Hirofumi Hamada; Naohide Yamashita; Koh Okumura; Tadao Kakizoe; Hideyuki Akaza; Makoto Fujime; Shirley Clift; Dale Ando; Richard Mulligan; Shigetaka Asano
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

8.  Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.

Authors:  Thomas Schwaab; Christopher P Tretter; Jennifer J Gibson; Bernard F Cole; Alan R Schned; Robert Harris; Eric M Wallen; Jan L Fisher; Mary G Waugh; Debra Truman; Laura M Stempkowski; Nancy A Crosby; John A Heaney; Marc S Ernstoff
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

Review 9.  Vaccine therapy in patients with renal cell carcinoma.

Authors:  Hein Van Poppel; Steven Joniau; Stefaan W Van Gool
Journal:  Eur Urol       Date:  2009-01-30       Impact factor: 20.096

Review 10.  Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer.

Authors:  C P S Potter; A L Harris
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more
  2 in total

1.  A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1.

Authors:  He Wang; Jiyun Yu; Li Li
Journal:  Onco Targets Ther       Date:  2015-10-23       Impact factor: 4.147

2.  Loss of KCNJ15 expression promotes malignant phenotypes and correlates with poor prognosis in renal carcinoma.

Authors:  Yang Liu; Han Wang; Beibei Ni; Jinghua Zhang; Shi Li; Yuqian Huang; Yanling Cai; Hongbing Mei; Zesong Li
Journal:  Cancer Manag Res       Date:  2019-02-07       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.